Utility of biochemical markers of bone turnover and bone mineral density in management of osteoporosis

Critical Reviews in Clinical Laboratory Sciences

Volumn 45, Issue 2, 2008, Pages 221-258

  Vasikaran, Samuel D ^a,b  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Alendronate; Alkaline phosphatase; Bisphosphonates; Bone formation; Bone loss; Bone mineral density; Bone resorption; Bone turnover; Deoxypyridinoline; Dual energy X ray absorptiometry; Fracture risk; Monitoring; Osteocalcin; Osteopenia; Osteoporotic fracture

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CONJUGATED ESTROGEN; HYDROXYPROLINE; OSTEOCALCIN; PARATHYROID HORMONE[1-34]; PLACEBO; PROCOLLAGEN; PYRIDINOLINE; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; TELOPEPTIDE; TESTOSTERONE; VITAMIN D; ZOLEDRONIC ACID;

BONE DENSITY; BONE REMODELING; BONE STRUCTURE; BONE TURNOVER; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; FRAGILITY FRACTURE; HORMONE SUBSTITUTION; HUMAN; MEASUREMENT; MONITORING; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

ANIMALS; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE RESORPTION; HUMANS; OSTEOPOROSIS;

EID: 42149165521     PISSN: 10408363     EISSN: 1549781X     Source Type: Journal    
DOI: 10.1080/10408360801949442     Document Type: Review

References (181)

1. Consensus Development Conference. Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993; 94: 646-650.
2. Kanis JA, Melton LJ, Christianson C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994; 9: 1137-1141.
3. Kanis JA, Gluer C-C. An update on diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisers, International Osteoporosis Foundation. Osteoporos Int 2000; 11: 192-202.
4. Lauritzen JB, Lund B. Risk of hip fracture after osteoporosis fractures. Acta Orthop Scand 1993; 64: 297-300.
5. Ross P, Genant H, Davis J, Miller PD, Wasnich RD. Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic women. Osteoporos Int 1993; 3: 120-126.
6. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332: 767-773.
7. Abrahamsen B, Stilgren LS, Hermann AP, Tofteng CL, Barenholdt O, Vestergaard P, Brot C, Nielson SP. Discordance between changes in bone mineral density measured at different skeletal sites in perimenopausal women - implications for assessment of bone loss and response to therapy: the Danish Osteoporosis Prevention Study. J Bone Miner Res 2001; 16: 1212-1219.
8. Faulkner KG. Bone matters: are density increases necessary to reduce fracture risk? J Bone Miner Res 2000; 15: 183-187.
9. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312: 1254-1259.
10. Siris ES, Chen YT, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE Berger ML. Bone mineral density thresholds for pharmacologic intervention to prevent fractures. Arch Intern Med 2004; 164: 1108-1112.
11. Robbins J, Aragaki AK, Kooperberg C, Watts N, Wactawski-Wende J, Jackson RD, LeBoff MS, Lewis CE, Chen Z, Stefanick ML, Cauley J. Factors associated with 5-year risk of hip fracture in postmenopausal women. JAMA 2007; 298: 2389-2398.
12. Melton LJ 3rd, Chrischilles EA, Cooper C, Lane AW, Riggs BL. Perspective. How many women have osteoporosis? J Bone Miner Res 1992; 7: 1005-1010.
13. Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001; 12: 989-995.
14. Herndon MB, Schwartz LM, Woloshin S, Welch HG. Implications of expanding disease definitions: the case of osteoporosis. Health Aff (Millwood) 2007; 26: 1702-1711.
15. Dennison E, Mohamed MA, Cooper C. Epidemiology of osteoporosis. Rheum Dis Clin North Am 2006; 32: 617-629.
16. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002; 359: 1761-1767.
17. Doherty DA, Sanders KM, Kotowicz MA, Prince RL. Lifetime and five-year age-specific risks of first and subsequent osteoporotic fractures in postmenopausal women. Osteoporos Int 2001; 12: 16-23.
18. Barrett-Connor E, Siris ES, Wehren LE, Miller PD, Abbott TA, Berger ML, Santora AC, Sherwood LM. Osteoporosis and fracture risk in women of different ethnic groups. J Bone Miner Res 2005; 20: 185-194.
19. Cauley JA, Lui L-Y, Ensrud KE, Zmuda JM, Stone KL, Hochberg MC, Cummings SR. Bone mineral density and the risk of incident nonspinal fractures in black and white women. JAMA 2005; 293: 2102-2108.
20. Lau EM, Lynn H, Woo J, Melton LJ. Areal and volumetric bone density in Hong Kong Chinese: a comparison with Caucasians living in the United States. Osteoporos Int 2003; 14: 583-588.
21. Cummings SR, Black DM, Rubin SM. Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Int Med 1989; 149: 2445-2448.
22. Kanis JA, Pitt FA. Epidemiology of osteoporosis. Bone 1992; 13(Suppl 1): S7-S15.
23. Kelsey JL, Browner W, Seeley D, Nevitt MC, Cummings SR. Risk factors for fractures of the distal forearm and proximal humerus. Am J Epidemiol 1992; 135: 447-489.
24. Jones G, Nguyen T, Sambrook PN, Kelly PJ, Gilbert C, Eisman JA. Symptomatic fracture incidence in elderly men and women: the Dubbo Osteoporosis Epidemiology Study (DOES). Osteoporos Int 1994; 4: 277-282.
25. Cooper C. Epidemiology and public health impact of osteoporosis. Baillieres Clin Rheumatol 1993; 7: 459-477.
26. Kanis JA, McCloskey EV. Epidemiology of vertebral osteoporosis. Bone 1992; 13(Suppl 2): S1-S10.
27. Eastell R, Cedel SL, Wahner HW, Riggs BL, Melton LJ 3rd. Classification of vertebral fractures. J Bone Miner Res 1991; 6: 207-215.
28. Melton LJ 3rd, Who has osteoporosis? A conflict between clinical and public health perspectives. J Bone Miner Res 2000; 15: 2309-2314.
29. Cooper C, Campion C, Melton LJ 3rd. Hip fractures in the elderly: a world-wide projection. Osteoporos Int 1992; 2: 285-289.
30. Todd CJ, Freeman CJ, Camilleri-Ferrante C, Palmer CR, Hyder A, Laxton CE, Parker MJ, Payne BV, Rushton N. Differences in mortality after fracture of hip: the east Anglian audit. BMJ 1995; 310: 904-908.
31. Keene GS, Parker MJ, Pryor GA. Morbidity and mortality after hip fractures. BMJ 1993; 307: 1248-1250.
32. Riggs BL, Melton LJ 3rd. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 1995; 17(Suppl 5): S505-S511.
33. Randell A, Sambrook PN, Nguyen TV, Lapsley H, Jones G, Kelly PJ, Eisman JA. Direct clinical and welfare costs of osteoporotic fractures in elderly men and women. Osteoporos Int 1995; 5: 427-432.
34. Ralston SH. Genetics of osteoporosis. Proc Nutr Soc 2007; 66: 158-165.
35. Rosen CJ. Pathogenesis of osteoporosis. Baillieres Best Pract Res Clin Endocrinol Metab 2000; 14: 181-193.
36. Melton LJ III. Epidemiology of fractures. In Riggs BL and Melton LJ III, Eds. Osteoporosis: Etiology, Diagnosis, and Management. Pp 225-247. Philadelphia: Lippincott-Raven, 1995.
37. Pollitzer WS, Anderson JB. Ethnic and genetic differences in bone mass: a review with a heredity vs environmental perspective. Am J Clin Nutr 1989; 50: 1244-1259.
38. Riggs BL, Melton LJ 3rd. Involutional osteoporosis. N Eng J Med 1986; 314: 1676-1686.
39. Khosla S, Riggs BL. Pathophysiology of age-related bone loss and osteoporosis. Endocrinol Metab Clin North Am 2005; 34: 1015-1030.
40. Klein-Nulend J, Nijweide PJ, Burger EH. Osteocyte and bone structure. Curr Osteoporos Rep 2003; 1: 5-10.
41. Baron R. Anatomy and ultrastructure of bone. In Favus MJ, Ed. Primer on Metabolic Bone Diseases and Disorders of Mineral Metabolism. Pp 3-9. New York: Raven Press, 1993.
42. Raisz LG. Physiology and pathophysiology of bone remodeling. Clin Chem 1999; 45: 1353-1358.
43. Parfitt AM. Skeletal heterogeneity and the purposes of bone remodeling: implications for the understanding of osteoporosis. In Marcus R, Feldman D, Kelsey J, Eds. Osteoporosis. 2nd Ed. Pp. 433-447. San Diego: Academic Press, 2001.
44. Parfitt AM. Targeted and non-targeted bone remodeling: relationship to BMU origination and progression. Bone 2002; 30: 5-7.
45. Eriksen EF. Normal and pathological remodelling of human trabecular bone: three-dimensional reconstruction of the remodelling sequence in normals and in metabolic bone disease. Endocr Rev 1986; 7: 379-408.
46. Jilka RL. Biology of the basic multicellular unit and the pathophysiology of osteoporosis. Med Pediatr Oncol 2003; 41: 182-185.
47. Chapurlat RD, Gamero P, Sornay-Rendu E, Arlot ME, Claustrat B, Delmas PD. Longitudinal study of bone loss in pre- and perimenopausal women: evidence for bone loss in perimenopausal women. Osteoporos Int 2000; 11: 493-498.
48. Darby AJ, Meunier PJ. Mean wall thickness and formation periods of trabecular bone packets in idiopathic osteoporosis. Calcif Tissue Int 1981; 33: 199-204.
49. Meunier PJ, Boivin G. Bone mineral density reflects bone mass but also the degree of mineralisation of bone: therapeutic implications. Bone 1997; 21: 373-377.
50. Lips P, Courpron P Meunier PJ. Mean wall thickness of trabecular bone packets in human iliac crest: changes with age. Calcif Tissue Int 1978; 26: 13-17.
51. Parfitt AM, Villanueva AR, Foldes J, Rao DS. Relations between histologic indices of bone formation: implications for the pathogenesis of spinal osteoporosis. J Bone Miner Res 1995; 10: 466-473.
52. Parfitt AM. Bone forming cells in clinical conditions. In Hall BK, Ed. Bone: A Treatise, Vol. 1, The Osteoblast and Osteocyte. Pp 351-429. Caldwell, NJ: Telford Press, 1990.
53. Jilka RL, Weinstein RS, Takahashi K, Parfitt AM, Manolagas SC. Linkage of decreased bone mass with impaired osteoblastogenesis in a murine model of accelerated senescence. J Clin Invest 1996; 97: 1732-1740.
54. Manolagas SC, Jilka RL. Bone marrow, cytokines and bone remodelling. Emerging insights into the pathophysiology of osteoporosis. N Eng J Med 1995; 332: 305-311.
55. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999; 20: 345-357.
56. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005; 115: 3318-3325.
57. Brown JP, Delmas PD, Arlot M, Meunier PJ. Active bone turnover of the corticoendosteal envelope in postmenopausal osteoporosis. J Clin Endocrinol Metab 1987; 64: 954-959.
58. Podenphant J, Johansen JS, Thomsen K, Riis BJ, Leth A, Christiansen C. Bone turnover in spinal osteoporosis. J Bone Miner Res 1987; 2: 497-503.
59. Panigrahi K, Delmas PD, Singer F, Ryan W, Reiss O, Fisher R, Mizrahi I, Darte C, Kress BC, Christenson H. Characteristics of a two-site immunoradiometric assay for human skeletal alkaline phosphatase in serum. Clin Chem 1994; 40: 822-825.
60. Garnero P, Delmas PD. Clinical usefulness of markers of bone remodelling in osteoporosis. In Meunier PJ, Ed. Osteoporosis: Diagnosis and management. Pp 79-101 London: Martin Dunitz, 1998.
61. Brown JP, Delmas PD, Malaval L, Edouard C, Chapuy MC, Meunier PJ. Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet 1984; 1: 1091-1093.
62. 47 calcium kinetics. Efficiency of serum bone gamma-carboxyglutamic acid containing protein, serum alkaline phosphatase and urinary hydroxyproline excretion. J Clin Invest 1985; 76: 2254-2258.
63. Parfitt AM, Simon LS, Villanueva AR, Krane SM. Procollagen type I carboxy-terminal extension peptide in serum as a marker of collagen biosynthesis in bone. Correlation with Iliac bone formation rates and comparison with total alkaline phosphatase. J Bone Miner Res 1987; 2: 427-436.
64. Ebeling PR, Peterson JM, Riggs BL. Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone diseases. J Bone Miner Res 1992; 7: 1243-1250.
65. Eriksen EF, Charles P, Melsen F, Mosekilde L, Risteli L, Risteli J. Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry. J Bone Miner Res 1993; 8: 127-132.
66. Charles P, Mosekilde L, Risteli L, Risteli J, Eriksen EF. Assessment of bone remodeling using biochemical indicators of type I collagen synthesis and degradation: relation to calcium kinetics. Bone Miner 1994; 24: 81-94.
67. Orum O, Hansen M, Jensen CH, Sørensen HA, Jensen LB, Hørslev-Petersen K, Teisner B. Procollagen type I N-terminal propeptide (PINP) as an indicator of type I collagen metabolism: ELISA development, reference interval, and hypovitaminosis D induced hyperparathyroidism. Bone 1996; 19: 157-163.
68. Alvarez L, Peris P, Pons F, Guañabens N, Herranz R, Monegal A, Bedini JL, Deulofeu R, Martínez de Osaba MJ, Muñoz-Gómez J, Ballesta AM. Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activity. Arthritis Rheum 1997; 40: 461-468.
69. Suvanto-Luukkonen E, Risteli L, Sundström H, Penttinen J, Kauppila A, Risteli J. Comparison of three serum assays for bone collagen formation during postmenopausal estrogen-progestin therapy. Clin Chim Acta 1997; 266: 105-116.
70. Seibel MJ. Biochemical markers of bone turnover: Part I: biochemistry and variability. Clin Biochem Rev 2005; 26: 97-122.
71. Dull T, Henneman P. Urinary hydroxyproline as an index of collagen turnover in bone. N Eng J Med 1963; 268: 132-134.
72. Krane SM, Kantrowitz FG, Byrne M, Pinnell SR, Singer FR. Urinary excretion of hydroxylysine and its glycosides as an index of collagen degradation. J Clin Invest 1977; 59: 819-827.
73. Prockop DJ, Kivirikko KJ, Tuderman L, Guzman NA. The biosynthesis of collagen and its disorders. N Engl J Med 1979; 301: 13-23.
74. Krane SM. Skeletal metabolism in Paget's disease of bone. Arthritis Rheum 1980; 23: 1087-1094.
75. Krane SM, Munoz AJ, Harris ED. Urinary polypeptides related to collagen synthesis. J Clin Inves 1970; 49: 716-729.
76. Reed P, Holbrook IB, Gardner ML, McMurray JR. Simple, optimized liquid-chromatographic method for measuring total hydroxyproline in urine evaluated. Clin Chem 1991; 37: 285-290.
77. Vasikaran SD, McCloskey EV, Kahn S, Kanis JA. Intra-individual variation in fasting urinary calcium- and hydroxyproline-creatinine ratio measured in metabolic bone clinic patients both as outpatients and inpatients. Ann Clin Biochem 1994; 31: 272-276.
78. Eyre D. New biomarkers of bone resorption. J Clin Endocrinol Metab 1992; 74: 470A-470C.
79. Delmas PD. Markers of bone formation and resorption. In Favus MJ, Ed. Primer on Metabolic Bone Diseases and Disorders of Mineral Metabolism. Pp 108-112. New York: Raven Press, 1993.
80. Eastell R, Hampton L, Colwell A, Green JR, Assiri AMA, Hesp R, Russell RGG, Reeve J. Urinary collagen crosslinks are highly correlated with radio-isotopic measurement of bone resorption In Christiansen C and Overgaard K. Eds. Osteoporosis. Pp 469-70. Copenhagen: Osteopress, 1990.
81. Colwell A, Eastell R, Assiri AMA, Russell RGG. In Christiansen C, Overgaard K, Eds. Effect of Diet on Deoxypyridinoline Excretion. Osteoporosis. Pp 590-591. Copenhagen: Osteopress, 1990.
82. Uebelhart D, Gineyts E, Chapuy MC, Delmas PD. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner 1990; 8: 87-96.
83. Eastell R, Calvo MS, Burritt MF, Ottord KP, Russell RGG, Riggs BC. Abnormalities in circadian patterns of bone formation and renal calcium conservation in type 1 osteoporosis. J Clin Endocrinol Metab 1992; 74: 487-494.
84. Colwell A, Russell RG, Eastell R. Factors affecting the assay of urinary 3-hydroxy pyridinium crosslinks of collagen as markers of bone resorption. Eur J Clin Invest 1993; 23: 341-349.
85. Seyedin SM, Kung VT, Daniloff YN Hesley RP, Gomez B, Nielsen LA, Rosen HN, Zuk RF. Immunoassay for urinary pyridinoline: the new marker of bone resorption. J Bone Miner Res 1993; 8: 635-641.
86. Robins SP, Woitge H, Hesley R, Ju J, Seyedin S, Seibel MJ. Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res 1994; 9: 1643-1649.
87. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 1993; 39: 35-40.
88. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 1994; 40: 2022-2025.
89. Fledelius C, Johnsen AH, Cloos PAC, Bonde M, Qvist P. Characterization of urinary degradation products derived from type I collagen. Identification of a beta-isomerized Asp-Gly sequence within the C-terminal telopeptide (alpha1) region. J Biol Chem 1997; 272: 9755-9763.
90. Bonde M, Fledelius C, Qvist P, Christiansen C. Coated-tube radioimmunoassay for C-telopeptides of type I collagen to assess bone resorption. Clin Chem 1996; 42: 1639-1644.
91. Bonde M, Garnero P, Fledelius C, Qvist P, Delmas PD, Christiansen C. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen. J Bone Miner Res 1997; 12: 1028-1034.
92. Rosenquist C, Fledelius C, Christgau S, Pedersen BJ, Bonde M, Qvist P, Christiansen C. Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem 1998; 44: 2281-2289.
93. Okabe R, Inaba M, Nakatsuka K, Miki T, Naka H, Moriguchi A, Nishizawa Y. Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline. J Bone Miner Metab 2004; 22: 127-131.
94. Christgau S, Rosenquist C, Alexandersen P, Bjarnason NH, Ravn P, Fledelius C, Herling C, Qvist P, Christiansen C. Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. Clin Chem 1998; 44: 2290-2300.
95. Hanson DA, Weis MA, Bollen AM, Maslan SL, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992; 7: 1251-1258.
96. Gertz BJ, Shao P, Hanson DA, Quan H, Harris ST, Genant HK, Chesnut CH 3rd, Eyre DR. Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine. J Bone Miner Res 1994; 9: 135-142.
97. Maeno Y, Inaba M, Okuno S, Yamakawa T, Ishimura E, Nishizawa Y. Serum concentrations of cross-linked N-telopeptides of type I collagen: new marker for bone resorption in hemodialysis patients. Clin Chem 2005; 51: 2312-2317.
98. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994; 79: 1693-1700.
99. Schlosser K, Scigalla P. Biochemical markers as surrogates in clinical trials in patients with metastatic bone disease and osteoporosis. Scand J Clin Lab Invest 1997; 227: 21-28.
100. Braga de Castro Machado A, Hannon R, Eastell R. Monitoring alendronate therapy for osteoporosis. J Bone Miner Res 1999; 14: 602-608.
101. Bell NH, Bilezikian JP, Bone HG 3rd, Kaur A, Maragoto A, Santora AC. Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women. MK-063 Study Group. J Clin Endocrinol Metab 2002; 87: 2792-2797.
102. Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 1998; 13: 1431-1438.
103. Garnero P, Gineyts E, Arbault P, Christiansen C, Delmas PD. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J Bone Miner Res 1995; 10: 641-649.
104. Rosen HN, Dresner-Pollak R, Moses AC, Rosenblatt M, Zeind AJ, Clemens JD, Greenspan SL. Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover. Calcif Tissue Int 1994; 54: 26-29.
105. Rosen HN, Moses AC, Garber J, Ross DS, Lee SL, Greenspan SL. Utility of biochemical markers of bone turnover in the follow-up of patients treated with bisphosphonates. Calcif Tissue Int 1998; 63: 363-368.
106. Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, McKeever C, Miller SS, Davidson M, Bolognese MA, Mulloy AL, Heyden N, Wu M, Kaur A, Lombardi A. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 137: 875-883.
107. Sambrook PN, Geusens P, Ribot C, Solimano JA, Ferrer-Barriendos J, Gaines K, Verbruggen N, Melton ME. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International. J Intern Med 2004; 255: 503-511.
108. Bone HG, Greenspan SL, McKeever C, Bell N, Davidson M, Downs RW, Emkey R, Meunier PJ, Miller SS, Mulloy AL, Recker RR, Weiss SR, Heyden N, Musliner T, Suryawanshi S, Yates AJ, Lombardi A. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab 2000; 85: 720-726.
109. Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002; 87: 985-992.
110. Roux C, Garnero P, Thomas T, Sabatier JP, Orcel P, Audran M. Recommendations for monitoring antiresorptive therapies in postmenopausal osteoporosis. Comité Scientifique du GRIO. Joint Bone Spine 2005; 72: 26-31.
111. Chesnut CH 3rd, Bell NH, Clark GS, Drinkwater BL, English SC, Johnson CC Jr, Notelovitz M, Rosen C, Cain DF, Flessland KA, Mallinak NJ. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 1997; 102: 29-37.
112. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. FLEX Research Group. JAMA. 2006; 296: 2927-2938.
113. Vasikaran SD, Khan S, McCloskey EV, Kanis JA. Sustained response to intravenous alendronate in postmenopausal osteoporosis. Bone 1995; 17: 517-520.
114. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. HORIZON Pivotal Fracture Trial. N Engl J Med 2007; 356: 1809-1822.
115. Jones GR. Effect of the reporting-interval size on critical difference estimation: beyond "2.77". Clin Chem. 2006; 52: 880-885.
116. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350: 459-468.
117. McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 2005; 165: 1762-1768.
118. Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, Dore RK, Correa-Rotter R, Papaioannou A, Cumming DC, Hodsman AB. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002; 87: 4528-4535.
119. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman N. Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin Endocrinol (Oxf) 2001; 54: 739-750.
120. Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004; 89: 503-510.
121. Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, Santanna J, Loh L, Lenrow DA, Holmes JH, Kapoor SC, Atkinson LE, Strom BL. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000; 85: 2670-2677.
122. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992; 75: 1092-1098.
123. Seibel MJ, Lang M, Geilenkeuser WJ. Interlaboratory variation of biochemical markers of bone turnover. Clin Chem 2001; 47: 1443-1450.
124. Gillett MJ, Vasikaran SD. Urinary NTX results rarely alter the clinical management of patients with osteoporosis in the tertiary hospital. Pathology 2006; 38: 49-52.
125. Physician's guide to prevention and treatment of osteoporosis. Washington (DC): National Osteoporosis Foundation; 2003. http://www.guideline.gov/summary/ summary.aspx?ss=15&doc id=3862 (accessed 05-03-2008).
126. Management of osteoporosis in postmenopausal women: 2006 position statement of the North American Menopause Society. Menopause 2006; 13: 340-367. http://www.menopause.org/ Portals/0/content/PDF/psosteo06.pdf (accessed 05-03-2008).
127. Scottish Intercollegiate Guidelines Network, Guideline No 71: Management of Osteoporosis. http://www.sign.ac.uk/guidelines/fulltext/71/index.html (accessed 05-03-2008).
128. The Royal Australian College Of General Practitioners. Guidelines for the management of postmenopausal osteoporosis for general practitioners. http://www.racgp.org.au/guidelines/osteoporosis (accessed 05-03-2008).
129. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 2000; 11(Suppl 6): S2-S17.
130. Eastell R, Colwell A, Hampton L, Reeve J. Biochemical markers of bone resorption compared with estimates of bone resorption from radiotracer kinetic studies in osteoporosis. J Bone Miner Res 1997; 12: 59-65.
131. Stepan JJ, Pospichal J, Presl J, Pacovsky V. Bone loss and biochemical indices of bone remodeling in surgically induced postmenopausal women. Bone 1987; 8: 279-284.
132. Garnero P, Sornay-Rendu E, Capuy MC, Delmas P. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 1996; 11: 337-349.
133. Khosla S, Melton LJ 3rd, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 1998; 83: 2266-2274.
134. Marcus R, Holloway L, Wells B, Greendale G, James MK, Wasilauskas C, Kelaghan J. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. J Bone Miner Res 1999; 14: 1583-1595.
135. Szulc P, Garnero P, Munoz F, Marchand F, Delmas PD. Cross-sectional evaluation of bone metabolism in men. J Bone Miner Res 2001; 16: 1642-1650.
136. Christiansen C, Riis BJ, Rodbro P. Prediction of rapid bone loss in postmenopausal women. Lancet 1987; 1: 1105-1108.
137. Christiansen C, Riis BJ, Rodbro P. Screening procedures for women at risk of developing postmenopausal osteoporosis. Osteoporos Int 1990; 1: 35-40.
138. Rosen CJ, Chesnut CH 3rd, Mallinak NJs. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement therapy or calcium supplementation. J Clin Endocrinol Metab 1997; 82: 1904-1910.
139. Mole PA, Walkinshaw MH, Robins SP, Paterson CR. Can urinary pyridinium crosslinks and urinary oestrogens predict bone mass and rate of bone loss after the menopause? Eur J Clin Invest 1992; 22: 767-771.
140. Reeve J, Pearson J, Mitchell A, Green J, Nicholls A, Justice J, Hudson E, Klenerman L. Evolution of spinal bone loss and biochemical markers of bone remodelling after menopause in normal women. Calcif Tissue Int 1995; 57: 105-110.
141. Cosman F, Nieves J, Wilkinson C, Schnering D, Shen V, Lindsay R. Bone density change and biochemical indices of skeletal turnover. Calcif Tissue Int 1996; 58: 236-243.
142. Ross PD, Knowlton W. Rapid bone loss is associated with increased levels of biochemical markers. J Bone Miner Res 1998; 13: 297-302.
143. Cheng S, Suominen H, Väänänen K, Käkönen SM, Pettersson K, Heikkinen E. Serum osteocalcin in relation to calcaneal bone mineral density in elderly men and women: a 5-year follow-up. J Bone Miner Metab 2002; 20: 49-56.
144. Dennison E, Eastell R, Fall CH, Kellingray S, Wood PJ, Cooper C. Determinants of bone loss in elderly men and women: a prospective population-based study. Osteoporos Int 1999; 10: 384-391.
145. Yoshimura N, Hashimoto T, Sakata K, Morioka S, Kasamatsu T, Cooper C. Biochemical markers of bone turnover and bone loss at the lumbar spine and femoral neck: the Taiji study. Calcif Tissue Int 1999; 65: 198-202.
146. Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, Cormier C, Bréart G, Meunier PJ, Delmas PD. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 1996; 11: 1531-1538.
147. Vergnaud P, Garnero P, Meunier PJ, Bŕeart G, Kamihagi K, Delmas PD. Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study. J Clin Endocrinol Metab 1997; 82: 719-724.
148. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000; 15: 1526-1536.
149. Ross PD, Kress BC, Parson RE, Wasnich RD, Armour KA, Mizrahi IA. Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study. Osteoporos Int 2000; 11: 76-82.
150. Van Daele PL, Seibel MJ, Burger H, Hofman A, Grobbee DE, van Leeuwen JP, Birkenhäger JC, Pols HA. Case control analysis of bone resorption markers, disability and hip fracture risk: the Rotterdam study. BMJ 1996; 312: 482-483.
151. Weel A, Seibel MJ, Pols HA. Which fractures are associated with high bone resorption in elderly women: The Rotterdam Study. J Bone Miner Res 1999; 14: S356.
152. Akesson K, Ljunghall S, Jonsson B, Sernbo I, Johnell O, Gärdsell P, Obrant KJ. Assessment of biochemical markers of bone metabolism in relation to the occurrence of fracture: a retrospective and prospective population-based study of women. J Bone Miner Res 1995; 10: 1823-1829.
153. Gerdhem P, Ivaska KK, Alatalo SL, Halleen JM, Hellman J, Isaksson A, Pettersson K, Väänänen HK, Akesson K, Obrant KJ. Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 2004; 19: 386-393.
154. Luukinen H, Käkönen SM, Pettersson K, Koski K, Laippala P, Lövgren T, Kivelä SL, Väänänen HK. Strong prediction of fractures among older adults by the ratio of carboxylated to total serum osteocalcin. J Bone Miner Res 2000; 15: 2473-2478.
155. Meier C, Nguyen TV, Center JR, Seibel MJ, Eisman JA. Bone resorption and osteoporotic fractures in elderly men: the dubbo osteoporosis epidemiology study. J Bone Miner Res 2005; 20: 579-587.
156. Johnell O, Odén A, De Laet C, Garnero P, Delmas PD, Kanis JA. Biochemical indices of bone turnover and the assessment of fracture probability. Osteoporos Int 2002; 13: 523-526.
157. Kanis JA, Johnell O, Oden A, De Laet C, Jonsson B, Dawson A. Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. Bone 2002; 30: 251-258.
158. Garnero P, Dargent-Molina P, Hans D, Schott AM, Bŕeart G, Meunier PJ, Delmas PD. Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study. Osteoporos Int 1998; 8: 563-569.
159. Schousboe JT, Bauer DC, Nyman JA, Kane RL, Melton LJ, Ensrud KE. Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy. Osteoporos Int 2007; 18: 201-210.
160. Bauer DC, Garnero P, Hochberg MC, Santora A, Delmas P, Ewing SK, Black DM. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. Fracture Intervention Research Group. J Bone Miner Res 2006; 21: 292-299.
161. Seibel MJ, Naganathan V, Barton I, Grauer A. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate. J Bone Miner Res 2004; 19: 323-329.
162. Delmas PD, Licata AA, Reginster JY, Crans GG, Chen P, Misurski DA, Wagman RB, Mitlak BH. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone 2006; 39: 237-243.
163. Riggs BL, Hodgson SF, O'Fallon WM, Chao EY, Wahner HW, Muhs JM, Cedel SL, Melton LJ. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990; 322: 802-809.
164. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000; 85: 231-236.
165. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002; 112: 281-289
166. Delmas PD, Seeman E. Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 2004; 34: 599-604.
167. Delmas PD. Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporos Int 2000; 11(Suppl 6): S66-S76.
168. Riggs BL, Melton LJ, O'Fallon WM. Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Bone 1996; 18(Suppl 3): S197-S201.
169. Bjarnason NH, Sarkar S, Duong T, Mitlak B, Delmas P, Christiansen C. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 2001; 12: 922-930.
170. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas P. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003; 18: 1051-1056.
171. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD; Fracture Intervention Trial Study Group. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 2004; 19: 1250-1258.
172. Sarkar S, Reginster JY, Crans GG, Diez-Perez A, Pinette KV, Delmas PD. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 2004; 19: 394-401.
173. Reginster JY, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D, Collette J. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 2004; 34: 344-351.
174. Dobnig H, Sipos A, Jiang Y, Fahrleitner-Pammer A, Ste-Marie LG, Gallagher JC, Pavo I, Wang J, Eriksen EF. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 2005; 90: 3970-3977.
175. Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 2005; 20: 962-970.
176. Bonnick SL, Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med 2006; 119(4 Suppl 1): S25-S31.
177. Eastell R, Krege JH, Chen P, Glass EV, Reginster JY. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin 2006; 22: 61-66.
178. Fink E, Cormier C, Steinmetz P, Kindermans C, Le Bouc Y, Souberbielle JC. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy. Osteoporos Int 2000; 11: 295-303.
179. Reginster JY, Henrotin Y, Christiansen C, Gamwell-Henriksen E, Bruyere, Collette J, Christgau S. Bone resorption in post-menopausal women with normal and low BMD assessed with biochemical markers specific for telopeptide derived degradation products of collagen type I. Calcif Tissue Int 2001; 69: 130-137.
180. Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 2005; 20: 1905-1911.
181. Szulc P, Kaufman JM, Delmas PD. Biochemical assessment of bone turnover and bone fragility in men. Osteoporos Int 2007; 18: 1451-1461.